Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine July 2010, 51 (7) 11A-12A;
  • Article
  • Info & Metrics
  • PDF
Loading

Targeting β-cells: Ichise and Harris provide an overview of current developments in β-cell biomarkers and radionuclide-based techniques under investigation to image β-cell mass and function.
Page 1001

Challenges in reversible ligands: Slifstein looks at receptor-binding radioligands that are not conducive to conventional PET quantification and at solutions that kinetic modelers use to address this problem, including a novel approach in an article in this issue of JNM.
Page 1005

PET/CT enterography in Crohn disease: Groshar and colleagues combine 18F-FDG PET and CT enterography in a single examination and correlate PET tracer uptake with CT enterography patterns of disease activity in patients with Crohn disease.
Page 1009

Figure

PET/CT in hyperglycemia and diabetes: Rabkin and colleagues assess whether the rate of detection of suspected infectious and inflammatory processes with 18F-FDG PET/CT is adversely affected by hyperglycemic or diabetic patient status.
Page 1015

Figure

Novel H3 receptor radioligand: Ashworth and colleagues evaluate a highly potent, selective, and brain-penetrating histamine H3 receptor as a PET radioligand and elucidate the dose–receptor occupancy relationship of this tracer in the human brain.
Page 1021

Figure

GABAergic dysfunction in essential tremor: Boecker and colleagues use 11C-flumazenil PET to calculate the availability of benzodiazepine receptor sites of the γ-aminobutyric acid complex in controls and patients with bilateral essential tremor.
Page 1030

Figure

β-blockade and adenosine MPI: Reyes and colleagues investigate the effect of oral β-blockers on the presence, extent, and severity of myocardial perfusion abnormality induced by adenosine in patients with coronary artery disease.
Page 1036

Figure

SPECT/CT and LVAD infection: Litzler and colleagues report experience with integrated molecular and anatomic hybrid imaging to assess infection in patients with left-ventricular-assist devices.
Page 1044

Figure

Renal toxicity in radionuclide therapy: Vegt and colleagues provide an educational overview of mechanisms of renal accumulation, techniques to reduce kidney damage, and nephrotoxicity risk factors in peptide-receptor radionuclide therapy and antibody fragment radioimmunotherapy.
Page 1049

GLP-1 receptor PET and SPECT: Wild and colleagues describe the preclinical evaluation of exendin-4–based radiopharmaceuticals for glucagon-like peptide-1 receptor PET/CT and SPECT/CT and discuss the potential for improved localization of small insulinomas.
Page 1059

Figure

Brain PET in conscious mice: Mizuma and colleagues detail the development of an in vivo PET imaging system for conscious mice and demonstrate its use in determining physiologic regional cerebral glucose metabolic rates.
Page 1068

PET and hypoxia in head and neck tumors: Hoeben and colleagues report on small-animal studies to determine whether a novel radiolabeled monoclonal antibody can allow early, noninvasive PET of hypoxia in head and neck tumor xenografts.
Page 1076

Figure

111In-NLS-trastuzumab RIT: Costantini and colleagues evaluate in mice the tumor growth–inhibitory properties and normal tissue toxicity of this agent combining trastuzumab with an Auger electron-emitting radionuclide to enhance HER2-targeted immunotherapy of breast cancer.
Page 1084

dCK-specific PET probes: Shu and colleagues describe the development of PET probes with improved metabolic stability and specificity for deoxycytidine kinase, a rate-limiting enzyme in the deoxyribonucleoside salvage pathway and a determinant of therapeutic activity in several prodrugs.
Page 1092

Figure

Tumor targeting of a humanized nanobody: Vaneycken and colleagues present a novel strategy to quickly generate humanized Nanobodies for molecular imaging and discuss the potential for improved targeting of cellular antigens.
Page 1099

MMP imaging in aneurysms: Razavian and colleagues investigate in a mouse model whether SPECT/CT imaging of matrix metalloproteinase activation in aneurysms helps to predict propensities for expansion.
Page 1107

Figure

Tenascin-C in myocardial ischemia: Taki and colleagues explore serial changes in expression of this extracellular matrix glycoprotein after myocardial ischemia and reperfusion in mice and describe the potential for monitoring myocardial injury and repair.
Page 1116

Figure

Cerenkov imaging of medical isotopes: Ruggiero and colleagues report on the use of inherent optical emissions from decay of radiopharmaceuticals for Cerenkov luminescence imaging of tumors in vivo and correlate results with those from immuno-PET studies.
Page 1123

Figure

Second-generation Affibody molecules: Ahlgren and colleagues assess the potential effects of reengineered and optimized Affibody molecules on HER2 targeting, using 111In-ABY-025, a novel tracer.
Page 1131

64Cu-DOTA-PEG diabody: Li and colleagues describe the development of a monodispersed DOTA-PEG–conjugated anti-TAG-72 diabody with low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.
Page 1139

Dynamic PET denoising: Christian and colleagues introduce a modified and highly constrained backprojection method for processing dynamic PET studies, with documented performance in phantom and small-animal scans.
Page 1147

131I RIT dose and response: Dewaraja and colleagues perform fully 3D dosimetry, coupling SPECT/CT at multiple time points with Monte Carlo–based voxel-by-voxel dosimetry to examine dose–response in patients undergoing 131I-tositumomab treatment for refractory B-cell lymphoma.
Page 1155

Figure

ON THE COVER

PET is generally conducted under anesthesia in laboratory animals to restrict movement, but it is important for animals to be conscious during physiologic brain imaging studies. The brain images displayed here, obtained with a new in vivo imaging system for conscious mice, show clear and well-correlated regional uptake of 18F-FDG for both PET and ex vivo autoradiography.

See page 1072.

Figure
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 51 (7)
Journal of Nuclear Medicine
Vol. 51, Issue 7
July 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Jul 2010, 51 (7) 11A-12A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Jul 2010, 51 (7) 11A-12A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • ON THE COVER
  • Info & Metrics
  • PDF

Related Articles

  • Imaging of β-Cell Mass and Function
  • When Reversible Ligands Do Not Reverse, and Other Modelers' Dilemmas
  • PET/CT Enterography in Crohn Disease: Correlation of Disease Activity on CT Enterography with 18F-FDG Uptake
  • Do Hyperglycemia and Diabetes Affect the Incidence of False-Negative 18F-FDG PET/CT Studies in Patients Evaluated for Infection or Inflammation and Cancer? A Comparative Analysis
  • Evaluation of 11C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET
  • GABAergic Dysfunction in Essential Tremor: An 11C-Flumazenil PET Study
  • Attenuation of Adenosine-Induced Myocardial Perfusion Heterogeneity by Atenolol and Other Cardioselective β-Adrenoceptor Blockers: A Crossover Myocardial Perfusion Imaging Study
  • Leukocyte SPECT/CT for Detecting Infection of Left-Ventricular-Assist Devices: Preliminary Results
  • Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention
  • Exendin-4–Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT
  • Establishment of In Vivo Brain Imaging Method in Conscious Mice
  • PET of Hypoxia with 89Zr-Labeled cG250-F(ab′)2 in Head and Neck Tumors
  • Antitumor Effects and Normal-Tissue Toxicity of 111In-Nuclear Localization Sequence-Trastuzumab in Athymic Mice Bearing HER-Positive Human Breast Cancer Xenografts
  • Novel PET Probes Specific for Deoxycytidine Kinase
  • In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT
  • Molecular Imaging of Matrix Metalloproteinase Activation to Predict Murine Aneurysm Expansion In Vivo
  • Dynamic Expression of Tenascin-C After Myocardial Ischemia and Reperfusion: Assessment by 125I-Anti–Tenascin-C Antibody Imaging
  • Cerenkov Luminescence Imaging of Medical Isotopes
  • Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold
  • Monodispersed DOTA-PEG–Conjugated Anti-TAG-72 Diabody Has Low Kidney Uptake and High Tumor-to-Blood Ratios Resulting in Improved 64Cu PET
  • Dynamic PET Denoising with HYPR Processing
  • 131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose–Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire